VTVT -78%
vTv Therapeutics Crashes on Alzheimer's Drug Study Failure
Shares of vTv Therapeutics, Inc. VTVT plummeted significantly after the company announced dismal results from the part A of the phase III trial, STEADFAST, on pipeline candidate, azeliragon.
vTv Therapeutics’ stock has plunged 50.6% in the last six months as against the industry’s decline of 18.9%.
The candidate was being evaluated in patients suffering from Alzheimer’s disease. The results showed that the candidate did not meet co-primary efficacy endpoint as patients taking azeliragon versus placebo did not improve in cognitive or functional outcomes as measured by the
Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinical Dementia [WIKI]Rating[/WIKI] Scale Sum of Boxes (CDR-sb).
...

https://finance.yahoo.com/news/vtv-t...141502023.html
vTv Therapeutics Crashes on Alzheimer's Drug Study Failure
Shares of vTv Therapeutics, Inc. VTVT plummeted significantly after the company announced dismal results from the part A of the phase III trial, STEADFAST, on pipeline candidate, azeliragon.
vTv Therapeutics’ stock has plunged 50.6% in the last six months as against the industry’s decline of 18.9%.
The candidate was being evaluated in patients suffering from Alzheimer’s disease. The results showed that the candidate did not meet co-primary efficacy endpoint as patients taking azeliragon versus placebo did not improve in cognitive or functional outcomes as measured by the
Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinical Dementia [WIKI]Rating[/WIKI] Scale Sum of Boxes (CDR-sb).
...
https://finance.yahoo.com/news/vtv-t...141502023.html
Kommentar